Navigation Links
Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
Date:9/4/2012

MADISON, Wis., Sept. 4, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Tuesday, September 11, 2012.  Mr. Palmin is scheduled to present at 10:50am ET in the Starlight North.  The event will be held September 9-11, at The Waldorf Astoria, 301 Park Avenue, New York, NY.

A live webcast of the Novelos presentation may be accessed via www.novelos.com

The webcast will be archived for 90 days following the presentation.

Information about the conference is available at www.rodm.com/conferences?id=176

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding.  CLR1502 (GLOW2) is a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.  Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit www.novelos.comINVESTOR CONTACTS J. Patrick Genn, Vice President of IR

Anne Marie Fields, Senior Vice PresidentNovelos Therapeutics, Inc.

LHAPh: (858) 775-7456

Ph: (212) 838-3777Email: jpgenn@novelos.com

Email: afields@lhai.com, @LHA_IR_PRNovelos Therapeutics, Inc.
Madison, Wisc.
Boston, Mass.
This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
2. Novelos Therapeutics Prices $5.4 Million Public Offering
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ENGLEWOOD, Colo. , Feb. 22, 2017  Aytu ... on global commercialization of novel products in the field ... sales team to up to 42 account managers from ... footprint. The sales force expansion is ... both prescriptions and revenues, an indication of increasing acceptance ...
(Date:2/22/2017)... According to a new market research report "Process Analytical Technology ... (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO & CMO) ... poised to reach USD 3.30 Billion by 2021 from USD 1.77 Billion ... Continue Reading ... ...
(Date:2/22/2017)... WOONSOCKET, R.I. , Feb. 22, 2017  CVS ... announce the removal of partially hydrogenated oils (PHO), the ... from all its exclusive store brands food products. The ... options which are free from artificial trans fats. This comes ... and Drug Administration,s deadline of June 2018 for processed ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as ... one of a small number of neurosurgeons in Michigan performing minimally invasive back ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael J. Hennessy ... platform connecting healthcare technology professionals and other key stakeholders with an array of ... starting on March 1, announced Michael J. Hennessy, Jr., president of MJH Associates. ...
(Date:2/22/2017)... ... 22, 2017 , ... Super-Sod will attend the Athens Home Show with a ... A shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit ... plant manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm ...
(Date:2/22/2017)... ... 2017 , ... FPS is a nonprofit mental health agency ... 1977, our organization was at the forefront in working with veterans with PTSD-related ... evident and served as the catalyst for the establishing the agency. , Run ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Safety, patient advocates stress that the patient context (age, illness and life choices) ... reasons to mitigate their occurrence. In addition, all too often, studies ...
Breaking Medicine News(10 mins):